Please wait a minute...
Reviews in Cardiovascular Medicine  2018, Vol. 19 Issue (3): 89-95     DOI: 10.31083/j.rcm.2018.03.3185
Review Previous articles | Next articles
Baroreflex stimulation for treating resistant hypertension: ready for the prime-time?
Davide Bolignano1, *(), Giuseppe Coppolino2
1 CNR-Institute of Clinical Physiology, Reggio Calabria, 89124, Italy
2 Renal Unit, Department of Health Sciences, "Magna Graecia" University, Catanzaro, 98100, Italy
Download:  PDF(1156KB)  ( 1110 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
The search of alternative methods for improving clinical management and outcomes of individuals affected by resistant hypertension has become a true health priority. In this review, we aimed at providing a timely overview and evidence synthesis on baroreflex activation therapy (BAT) and endovascular baroreflex amplification (EBA), two device-based therapies which rely on the principle of lowering blood pressure by stimulating the carotid baroreflex to decrease the sympathetic and enhance the parasympathetic activity. In resistant forms of arterial hypertension, accruing evidence has confirmed the capacity of these techniques to improve blood pressure control and to reduce the amount of anti-hypertensive therapy at cost of few side effects. Future results from ongoing randomized sham-controlled trials are eagerly awaited to best define the efficacy, safety and durability of effects in the long term before such an invasive approach may be considered as a suitable option in daily clinical practice.
Key words:  Resistant hypertension      baroreflex activation therapy      endovascular baroreflex amplification     
Published:  30 September 2018     
*Corresponding Author(s):  Davide Bolignano, E-mail: davide.bolignano@gmail.com   

Cite this article: 

Davide Bolignano, Giuseppe Coppolino. Baroreflex stimulation for treating resistant hypertension: ready for the prime-time?. Reviews in Cardiovascular Medicine, 2018, 19(3): 89-95.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm.2018.03.3185     OR     https://rcm.imrpress.com/EN/Y2018/V19/I3/89

[1] Bakris G, Nadim M, Haller H, et al. Baroreflex activation therapy safely reduces blood pressure for at least five years in a large resistant hypertension cohort. Journal of the American Society of Hypertension. 2014;8:e9-e10.
[2] Bakris G, Nadim M, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. Journal of the American Society Hypertension. 2012;6:152-158.
[3] Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. Journal of the American College of Cardiology. 2011;58:765-773.
[4] Brunner-La Rocca HP, Esler MD, Jennings GL, et al. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. European Heart Journal. 2001;22:1136-1143.
[5] Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419.
[6] Chapleau MW, Li Z, Meyrelles SS, et al. Mechanisms determining sensitivity of baroreceptor afferents in health and disease. Annals of the New York Academy of Sciences. 2001;940:1-19.
[7] de Leeuw PW, Alnima T, Lovett E, et al. Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension. 2015;65:187-192.
[8] Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129:e280-e292.
[9] Gronda E, Seravalle G, Brambilla G, et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. European Journal of Heart Failure. 2014;16:977-983.
[10] Hajduczok G, Chapleau MW, Ferlic RJ, et al. Gadolinium inhibits mechanoelectrical transduction in rabbit carotid baroreceptors. Implication of stretch-activated channels. Journal of Clinical Investigation. 1994;94:2392-2396.
[11] Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. Journal of the American Society of Hypertension. 2012;6:270-276.
[12] Joles JA and Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension.2004;3:699-706.
[13] Jones DW and Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension. 2004;3:1-3.
[14] Kearney PM, Wheltin M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
[15] Lembo G, Capaldo B, Rendina V, et al. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. American Physiological Society Journal. 1994;266:242-247.
[16] Mancia G and Grassi G. The autonomic nervous system and hypertension. Circulation Research. 2014;14:804-814.
[17] Masuo K, Mikami H, Ogihara T, et al. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. American Journal of Hypertension. 1997;10:77-83.
[18] May M, Ahrens J, Menne J, et al. Limited acute influences of electrical baroreceptor activation on insulin sensitivity and glucose delivery: a randomized, double-blind, crossover clinical study. Diabetes. 2014;63:2833-28837.
[19] Roberie DR and Elliott WJ. What is the prevalence of resistant hypertension in the United States? Current Opin Cardiol.2012;7:86-91.
[20] Roger VL, Go AS, Lloyd-jones DM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-e209.
[21] Sander GE and Giles TD. Resistant hypertension: concepts and approach to management. Current Hypertension Reports. 2011;3:347-355.
[22] Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension--its identification and epidemiology. Nature Reviews Nephrology. 2013;9:51-58.
[23] Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multicenter feasibility study. Journal of the American College of Cardiology. 2010;56:1254-1258.
[24] Spiering W, Williams B, Van Der Heyden J, et al. Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet. 2017;390:2655-2661.
[25] Tordoir JH, Scheffers I, Schmidli J, et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. European Journal of Vascular and Endovascular Surgery. 2007;33:414-421.
[26] Wallbach M, Lehnig LY, Schroer C, et al. Impact of baroreflex activation therapy on renal function--a pilot study. American Journal of Nephrology. 2014;40:371-380.
[27] Wallbach M, Lehnig LY, Schroer C, et al. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension. Hypertension. 2016;7:1-9.
[28] Wustmann K, Kucera JP, Scheffers I, et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension. 2009;54:530-536.
[1] Davide Bolignano, Giuseppe Coppolino. Renal nerve ablation for resistant hypertension: facts, fictions and future directions[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 9-18.
[2] Bashar Hannawi, Homam Ibrahim, Colin M. Barker. Renal Denervation: Past, Present, and Future[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 114-124.
[3] Sabas I. Gomez, Pablo Urbandt, Nirat Beohar, Orlando Santana. Renal Denervation: Current Status and Future Applications[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 351-357.
[4] Timothy R. Larsen, Wadie David, Susan Steigerwalt, Shukri David. Primary Hyperaldosteronism Decoded: A Case of Curable Resistant Hypertension[J]. Reviews in Cardiovascular Medicine, 2012, 13(4): 203-208.
No Suggested Reading articles found!